In her new role, Visconti is responsible for the creative agency’s marketing intelligence services as well as the teams that contribute to enhancing client decision-making and “optimizing the impact of client marketing campaigns.”
Visconti is a digital marketing and analytics veteran, having worked in the field since 2007. She has previously held roles at BioteMedical, a bioidentical hormone replacement therapies provider, as well as Belo + Company, a consumer agency. She also currently serves as a professor of digital marketing and analytics at Southern Methodist University.
“Rebecca brings a wealth of technical and analytical experience to her leadership role at AbelsonTaylor, which is absolutely essential in developing effective marketing campaigns in today’s data-intensive world,” Christopher Dimmock, AbelsonTaylor’s SVP of integrated strategy, said in a statement. “But she also brings strong marketing, team-building, and collaboration skills and the ability to use fact-based information to drive measurable business success.”
For her part, Visconti said she is thrilled to be working with AbelsonTaylor’s team of data architects and data visualization experts to advance the organization’s mission forward.
“This is an exciting time to be in healthcare marketing and I’m glad to be part of the pioneering work being done at AbelsonTaylor,” she said in a statement.
Visconti’s appointment is the latest in a series of personnel moves that the 2022 MM+M Agency 100 honoree has made this year.
During the spring, the agency also announced the hire of Jeremy Vannatta as VP, account director. In this role, Vannatta oversees AbelsonTaylor’s oncology clients and reports to EVP and director of client services Lynnette Hunter.
The agency has been on a steady trajectory amid significant industry-wide disruptions related to the COVID-19 pandemic.
In 2021, revenue rose 13%, to $64.8 million, up from $57.2 million in 2020. Meanwhile, the agency secured assignments from Coherus BioSciences, Arcutis Biotherapeutics, Cooper-Surgical and Aerovate Therapeutics.